Logo

BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk Melanoma and PD-L1

Share this

BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk Melanoma and PD-L1

Shots:

  • The P-III CheckMate -915 study involves assessing of Opdivo (240mg- IV- q2w) in combination with Yervoy (1 mg/kg- q6w) vs Opdivo (480mg- q4w) as monothx. as the adjuvant therapy in 1-943 patients who have had complete surgical removal of stage IIIb/c/d or stage IV melanoma
  • The P-III CheckMate -915 study did not meet its 1EPs of recurrence-free survival in patients with tumors PD-L1 <1% expression. The study will continue to assess 1EPs of RFS in IIT population- recommended by the Data Monitoring Committee
  • Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response while Yervoy is mAb targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) thus blocking its interaction with its ligands- CD80/CD86

Click here to­ read full press release/ article 

Ref: BMS | Image: BMS 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions